Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study.
about
Current and emerging azole antifungal agentsPhase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemiaCentral venous catheter (CVC) removal for patients of all ages with candidaemiaAntifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong KongImpact of an intravenous fluconazole restriction policy on patient outcomes.ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patientsLipid-based amphotericin B for the treatment of fungal infections.Role of newer azoles in surgical patients.Treatment of intra-abdominal abscesses caused by Candida albicans with antifungal agents and recombinant murine granulocyte colony-stimulating factorCanadian clinical practice guidelines for invasive candidiasis in adults.A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America.Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Catheter-related bloodstream infections, part I: pathogenesis, diagnosis, and management.Catheter-related bloodstream infections, part II: specific pathogens and prevention.In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model.Systemic antifungal therapy: new options, new challenges.Emerging azole antifungals.Clinical pharmacology of antifungal agents in pediatric patients.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Role of Dectin-2 for host defense against systemic infection with Candida glabrata.Antifungals to treat Candida albicans.Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy.Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis.[Strategies for antifungal treatment failure in intensive care units].Antifungal therapy in 'bone marrow failure'.Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.Candida infections in solid organ transplantation.Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis.Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole.Drug-Induced Kidney Injury in the Elderly.An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive MycosesComparative Proteomic Analysis of Candida albicans and Candida glabrata
P2860
Q24550733-08BA21A3-048A-4449-AB10-B995223C4D62Q24563657-DB653713-93EC-4E4A-BF96-2E9FF97B13BFQ26471135-9C47D9C7-CCA4-4C76-8E0E-E79F2659AA6FQ28388030-89AEC2FC-4AF1-4182-ABC4-93BC1985BE4EQ31989784-13D07F05-6B25-40D6-AC35-B4A3863B2B6FQ33573788-82083F2E-9DC5-4917-BB1D-66AC576D7249Q33604227-7D6C8606-176D-4F82-B0D7-571C0BE32D95Q33840089-7D64259F-CC70-4802-8C85-DC4527DE3C96Q34230759-E8380460-F4BA-4D56-86CB-4279199FA221Q34237335-7DC8AC06-64FA-438B-B891-EA5B5FF9AD63Q34335250-68E71D43-FAB8-46DF-B0CE-0EFADE3BDB9CQ34490092-34677C6C-074C-42F8-B47D-D9A2419A2D02Q34505582-DED63B1A-2FD7-4B11-96EB-A3F48EDD78FAQ35039499-D1D36715-5A31-422B-8BCB-0AAAB4DA01DDQ35071110-69EA429B-DD66-4F1F-8890-2CCDB4481AE3Q35136251-330347EB-AEDF-49D5-8854-31503EBE76D8Q35318531-B8972C4A-839E-4867-8B28-A5535CA0E7A2Q35585219-211DF5FE-621E-40F6-9AF0-E3FB5AF0B25AQ36066009-EE4A5B70-6293-4F75-B1C8-2AD1B7061E41Q36968140-50114F3B-DC07-406E-8263-EC52FBB6256AQ37469829-D2074A94-3C62-4CC4-B8E5-8B65093542A5Q37643830-6AA9D99B-00F0-4181-A34A-A7A85A1299CEQ37763928-FEB9A53A-5870-4DC4-8289-C15E71C499C2Q37889382-C4019645-E036-4AD2-8FCF-30227C1751B7Q38056762-3568403F-1745-42CD-86FC-2A506C0642E5Q38284468-28BF4048-3131-420E-838B-C78D93C371ADQ38531765-E2C912D8-77B1-479E-B60C-4C2F665767C8Q41010354-372D816F-277B-42C3-A778-AFEDA93CD029Q41733799-EDF3033E-1034-4545-9D63-5FA7D871A46CQ41753239-980D7823-0B7F-4172-B921-57B37694698BQ42272295-341F605E-D30C-4E86-8C21-CD3BF31437FDQ43696321-918B470F-1733-40CF-82FC-9D8903F7E874Q44073053-01F987D6-DB97-488F-8804-85AFADB74A2AQ45065480-BD19EAC2-BB58-404D-9C65-EA2B2871C806Q54394711-94CB42E4-0B58-4353-ABB6-8361E0F5F1A1Q56837353-40FA4B1C-5C5D-4D71-A8E5-7523D6B77681Q58482730-AB2AB5BE-D190-4ED6-82E6-C46C4A61CCCD
P2860
Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Fluconazole versus amphoterici ...... iasis: a matched cohort study.
@en
type
label
Fluconazole versus amphoterici ...... iasis: a matched cohort study.
@en
prefLabel
Fluconazole versus amphoterici ...... iasis: a matched cohort study.
@en
P2093
P1476
Fluconazole versus amphoterici ...... iasis: a matched cohort study.
@en
P2093
Abi-Said D
Anaissie EJ
Gilbreath J
Kontoyiannis DP
Papadakis K
Pinczowski H
P304
P356
10.1016/S0002-9343(96)80072-6
P407
P577
1996-08-01T00:00:00Z